Precise hepatic base editing of ASGR1 enables robust and durable LDLR-independent lipid lowering in vivo.
Gene editing in liver achieved cholesterol lowering without relying on the LDL receptor, offering hope for patients with severe hereditary high cholesterol unresponsive to current drugs.
This Molecular Therapy study demonstrates that precise base editing of the ASGR1 gene in the liver achieves sustained and significant lipid lowering independent of the LDL receptor pathway, an approach directly applicable to homozygous familial hypercholesterolemia patients in whom all current therapies depend on residual LDLR function. The LDLR-independence of this approach is the key novel feature, expanding the potential patient population for gene-based lipid therapy.
What the study was
- Study design
- preclinical_in_vivo
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Mol Ther
Why it surfaced
Addresses a critical gap in rare disease therapy: HoFH patients with no LDLR function are refractory to all statin and PCSK9 inhibitor approaches; ASGR1 base editing offers an entirely orthogonal mechanism; published in Molecular Therapy by an experienced gene editing group.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.